Compare SPHR & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPHR | ABCL |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.1B |
| IPO Year | 2019 | 2020 |
| Metric | SPHR | ABCL |
|---|---|---|
| Price | $103.93 | $12.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 12 |
| Target Price | ★ $169.08 | $16.82 |
| AVG Volume (30 Days) | 829.6K | ★ 4.9M |
| Earning Date | 11-03-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 113.03 | 10.91 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,220,045,000.00 | $75,128,000.00 |
| Revenue This Year | $11.02 | N/A |
| Revenue Next Year | $0.05 | $7.12 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 18.81 | ★ 160.56 |
| 52 Week Low | $58.18 | $2.75 |
| 52 Week High | $181.63 | $14.98 |
| Indicator | SPHR | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 22.96 | 52.08 |
| Support Level | $89.02 | $11.78 |
| Resistance Level | $119.30 | $12.88 |
| Average True Range (ATR) | 6.25 | 0.83 |
| MACD | -2.82 | -0.24 |
| Stochastic Oscillator | 5.14 | 27.97 |
Sphere Entertainment Co is a live entertainment and media company. The firm creates, writes, casts, produces, and tours shows and events. The group has two reportable segments: Sphere and MSG Networks. Sphere is a next-generation entertainment medium, and MSG Networks operates two regional sports and entertainment networks, as well as a direct-to-consumer (DTC) and authenticated streaming product.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.